PL334833A1 - Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity - Google Patents
Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesityInfo
- Publication number
- PL334833A1 PL334833A1 PL98334833A PL33483398A PL334833A1 PL 334833 A1 PL334833 A1 PL 334833A1 PL 98334833 A PL98334833 A PL 98334833A PL 33483398 A PL33483398 A PL 33483398A PL 334833 A1 PL334833 A1 PL 334833A1
- Authority
- PL
- Poland
- Prior art keywords
- thiazolobenzenosulphonamides
- obesity
- treating diabetes
- beta3
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (fr) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES UTILISES COMME AGONISTES β3 POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL334833A1 true PL334833A1 (en) | 2000-03-27 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98334833A PL334833A1 (en) | 1997-01-28 | 1998-01-23 | Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (fr) |
| JP (1) | JP2001509166A (fr) |
| KR (1) | KR20000070568A (fr) |
| CN (1) | CN1251099A (fr) |
| AR (1) | AR011092A1 (fr) |
| AU (1) | AU728812B2 (fr) |
| BG (1) | BG103686A (fr) |
| BR (1) | BR9807096A (fr) |
| CA (1) | CA2278739A1 (fr) |
| EA (1) | EA199900692A1 (fr) |
| EE (1) | EE9900328A (fr) |
| HR (1) | HRP980044A2 (fr) |
| HU (1) | HUP0002053A3 (fr) |
| ID (1) | ID22273A (fr) |
| IL (1) | IL131130A0 (fr) |
| IS (1) | IS5131A (fr) |
| NO (1) | NO993646L (fr) |
| PE (1) | PE52299A1 (fr) |
| PL (1) | PL334833A1 (fr) |
| SK (1) | SK100099A3 (fr) |
| TR (1) | TR199902442T2 (fr) |
| WO (1) | WO1998032753A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| EP1258253A1 (fr) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Nouveaux remedes et utilisation d'un agoniste beta3 |
| TR200401359T4 (tr) | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | İkame edilmiş piridinlerin hazırlanmasına yönelik işlem |
| JP4988128B2 (ja) * | 2000-07-13 | 2012-08-01 | イーライ リリー アンド カンパニー | β３アドレナリン作動性アゴニスト |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| CA2421594A1 (fr) | 2000-11-10 | 2002-05-16 | John Arnold Werner | Agonistes du recepteur beta-3 d'oxindole 3-substitue |
| AU2002221080A1 (en) * | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| ES2255621T3 (es) * | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
| ES2272749T3 (es) | 2001-08-14 | 2007-05-01 | Eli Lilly And Company | Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2. |
| CA2463441A1 (fr) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Heterocycles utiles pour le traitement de l'obesite |
| JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
| ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
| US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
| WO2006132196A1 (fr) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3 |
| PE20070458A1 (es) | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
| EP1940842B1 (fr) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
| EP1937264B1 (fr) * | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire |
| EP2698157B1 (fr) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3239170B1 (fr) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
| EP3241839B1 (fr) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
| CA2741125A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques |
| WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
| WO2011041293A1 (fr) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose |
| WO2011097079A1 (fr) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase 1 régulant le signal d'apoptose |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP2677869B1 (fr) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
| AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
| CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法 |
| WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
| EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
| EP3558298A4 (fr) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (fr) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-23 EE EEP199900328A patent/EE9900328A/xx unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 CA CA002278739A patent/CA2278739A1/fr not_active Abandoned
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/fr not_active Withdrawn
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/fr not_active Application Discontinuation
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Application Discontinuation
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9807096A (pt) | 2000-04-18 |
| WO1998032753A1 (fr) | 1998-07-30 |
| IS5131A (is) | 1999-07-23 |
| HUP0002053A2 (hu) | 2001-08-28 |
| ID22273A (id) | 1999-09-23 |
| EE9900328A (et) | 2000-02-15 |
| PE52299A1 (es) | 1999-05-26 |
| NO993646L (no) | 1999-09-27 |
| TR199902442T2 (xx) | 2000-07-21 |
| CA2278739A1 (fr) | 1998-07-30 |
| AR011092A1 (es) | 2000-08-02 |
| EA199900692A1 (ru) | 2000-02-28 |
| HRP980044A2 (en) | 1998-10-31 |
| HUP0002053A3 (en) | 2001-09-28 |
| JP2001509166A (ja) | 2001-07-10 |
| AU6038498A (en) | 1998-08-18 |
| BG103686A (bg) | 2000-06-30 |
| NO993646D0 (no) | 1999-07-27 |
| AU728812B2 (en) | 2001-01-18 |
| EP0968209A1 (fr) | 2000-01-05 |
| CN1251099A (zh) | 2000-04-19 |
| IL131130A0 (en) | 2001-01-28 |
| KR20000070568A (ko) | 2000-11-25 |
| SK100099A3 (en) | 2000-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL334833A1 (en) | Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity | |
| EP0915847A4 (fr) | Sulfonamides substitues utilises en tant qu'agonistes selectifs des recepteurs beta3 et destines au traitement des diabetes et de l'obesite | |
| HU9602951D0 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| HK1031174A1 (en) | Compositions and methods for treating diabetes | |
| AU3374897A (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| GR20010300044T1 (en) | Transfected cells and methods for treating diabetes | |
| EP0996497A4 (fr) | Dispositif et procede de traitement de liquide | |
| GB9828721D0 (en) | Novel apparatus and process | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| PL338082A1 (en) | Methods of treating obesity | |
| HUP0101779A3 (en) | Process for de-chlorinating and de-fouling waste-oil | |
| ZA200006866B (en) | Device and method for treating electroconductive endless material. | |
| GB9808470D0 (en) | Novel process and apparatus | |
| HK1027225A1 (en) | Device and process for telecommunication | |
| GB9606076D0 (en) | Diabetes treatment | |
| IL145220A0 (en) | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process | |
| GB2322184B (en) | Thermal treatment apparatus | |
| EP1007041A4 (fr) | Composition analgesique | |
| HK1023626A1 (en) | Organic photoconductor and treatment therefor | |
| HUP0003187A3 (en) | Substituted benzothiophenes and process for preparing them | |
| GB9717251D0 (en) | Process and apparatus | |
| EP1161242A4 (fr) | Composition et methode de traitement du diabete | |
| GB9604102D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| EP0959110A4 (fr) | Materiau et procede de traitement de surface | |
| GB9618290D0 (en) | Treatment of diabetes |